Drug developer Pharmos has focused its attention on the central nervous system. Its stable of drug candidates aim to treat conditions such as pain, inflammation, and autoimmune conditions. It gained its lead candidate dextofisopam when it acquired Vela Pharmaceuticals; the compound is a potential treatment for irritable bowel syndrome, a condition associated with the "brain-gut axis," or the connection between the nervous system and the intestines. Pharmos has also discovered several compounds in-house using its expertise in cannabinoid compounds (the kind without psychotropic effects). It is investigating several such compounds as treatments for pain and inflammation.